Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 1.00 |
| ▸ | CDC7 | O00311 | 4/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.50 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | MARK3 | P27448 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748429 | 0.84 | GSK3B (0.72) | GSK3BXDHSMN1; SMN2 | |
| SCHEMBL4643669 | 0.84 | GSK3B (0.72) | GSK3BMAPK1XDHSMN1; SMN2 | |
| SCHEMBL5400045 | 0.81 | GSK3B (0.69) | GSK3BXDHSMN1; SMN2 | |
| SCHEMBL5377580 | 0.80 | GSK3B (0.87) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL5380569 | 0.79 | GSK3B (0.73) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL5381098 | 0.79 | XDH (0.72) | GSK3BXDH | |
| SCHEMBL5384159 | 0.78 | GSK3B (0.64) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL3143657 | 0.78 | GSK3B (0.64) | GSK3BCDC7SMN1; SMN2 | |
| SCHEMBL5377691 | 0.78 | GSK3B (1.00) | GSK3BCDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL3854866 | 0.78 | SMN1; SMN2 (0.74) | GSK3BCDC7ROCK2MAP4K4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084793-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200231549-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-10654810-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180325900-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| EP-1115721-B1 | PYRIMIDONE DERIVATIVES | MITSUBISHI CHEM CORP (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1115721-A1 | PYRIMIDONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018758-A1 | PYRIMIDONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-04-06 | — | — | WO | disclosed |
| US-4725600-A | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0168262-A2 | Pyrimidine derivatives, processes for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231549-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GSK3B 1159/4885CDC7 905/4885ROCK2 1039/4885 |
| US-10654810-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | GSK3B 1159/4885CDC7 905/4885ROCK2 1039/4885 |
| US-11084793-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | GSK3B 1159/4885CDC7 905/4885ROCK2 1039/4885 |
| US-20180325900-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GSK3B 1159/4885CDC7 905/4885ROCK2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.